One of the most common respiratory diseases in the world is chronic obstructive pulmonary disease (COPD). COPD is an incurable disease that progresses slowly.

The most common symptoms of COPD are shortness of breath and coughing fits.¹

It is a very difficult disease to treat. ² One of the causes of this lung disease is tobacco smoke from smoking tobacco or passive inhalation of second-hand tobacco smoke.³ COPD also occurs due to chronic inflammation, which can occur due to frequent respiratory infections. This leads to thickening of the walls of the airways, increased mucus production, severe coughing, and, ultimately, permanent changes in the structure of the lungs.⁴

To strengthen the immunity of the respiratory tract and cleanse the bronchi of infected cells, experts recommend inhalations with Arecur.⁵ The drug in ampoule form is used to prepare inhalations: 2 ml of Arecur + 3 ml of water for injection should be mixed in a nebulizer and breathe calmly for 10-12 minutes, the course of treatment is 10 inhalations.

It should also be noted that patients with chronic lung diseases have an increased risk of cancer.⁶ Therefore, timely and complete cancer prevention with Arecur is extremely important.

 


1. Yawn BP, Mintz ML, Doherty DE. GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289-299.
2. Unninayar, Dana et al. "Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations." International journal of chronic obstructive pulmonary disease vol. 16 545-552. 2 March 2021.
3. Postma DS, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet. 2015;385(9971):899–909. 
4. Yawn BP, Mintz ML, Doherty DE. GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2021;16:289-299.
5. Panashchuk I, Tatskyi O, COPD: Perspectives of Immune Peptide Therapy and Lung Cancer Prevention, American Journal of Internal Medicine. Vol. 9, No. 6, 2021, pp. 248-252. doi: 10.11648/j.ajim.20210906.11
6. Zhang X, Jiang N, Wang L, Liu H, He R. Chronic obstructive pulmonary disease and risk of lung cancer: a meta-analysis of prospective cohort studies. Oncotarget. 2017;8(44):78044-78056.